Sarcopenia in Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)Sarcopenia
- Registration Number
- NCT07178197
- Lead Sponsor
- Mersin University
- Brief Summary
Sarcopenia negatively affects the prognosis of chronic diseases. However, the importance of sarcopenia in patients with idiopathic pulmonary fibrosis (IPF) has been less emphasized. The aim of the study is to determine the prevalence of sarcopenia in patients with IPF and to evaluate the impact of sarcopenia on quality of life and disease progression.
This study was designed as a descriptive cross-sectional. The study included patients diagnosed with IPF. Hand dynamometry and bioelectrical impedance analysis (BIA) were used to for diagnose of sarcopenia. Pulmonary function tests, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) measurements were examined. The 6-minute walk distance (6MWD) and 4-meter walking speed were recorded. The St. George Respiratory Questionnaire (SGRQ) was used to assess quality of life. All patients were evaluated for progressive disease.
- Detailed Description
The study was designed as a cross-sectional study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Being over 18 years of age
- Signing the informed consent form
- Having a diagnosis of IPF for at least one month
- Pregnancy
- History of cancer within the last 5 years
- History of lung surgery
- History of neuromuscular disease
- Active pulmonary tuberculosis
- Active respiratory tract infection
- Inability to perform pulmonary function tests
- Presence of a pacemaker
- History of systemic steroid use within the past 3 months
- Inability to use a hand dynamometer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hand Grip Strength through study completion, an average of 1 year Hand Grip Strength (kg)- Grip strength measurement using a hand dynamometer
SMI (skeletal muscle mass index) through study completion, an average of 1 year SMI (skeletal muscle mass index) (kg/m2) - SMI measurement using the Bioelectrical Impedance Analysis (BIA) device
Forced Expiratory Volume in 1 second (FEV1) through study completion, an average of 1 year Measurement of FEV1 for the assessment of pulmonary function
Forced Vital Capacity (FVC) through study completion, an average of 1 year Measurement of FVC for the assessment of pulmonary function
Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO) through study completion, an average of 1 year Measurement of DLCO for the assessment of pulmonary function.
Total Lung Capacity (TLC) through study completion, an average of 1 year Measurement of TLC for the assessment of pulmonary function.
Respiratory Muscle Strength through study completion, an average of 1 year Measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) for assessment of respiratory muscle strength
Six Minute Walk Test (6MWT) through study completion, an average of 1 year Distance walked in six minutes (m)
Gait speed through study completion, an average of 1 year 4-meter walking speed (m/s)
St. George's Respiratory Questionnaire (SGRQ) through study completion, an average of 1 year The questionnaire is designed to measure quality of life. It consists of symptom, activity, impact, and total scores. Each score ranges from 0 to 100. High scores indicate lower quality of life.
Progressive Disease through study completion, an average of 1 year Examination of all participants from clinical, physiological, and radiological perspectives
- Secondary Outcome Measures
Name Time Method Body Mass Index ( BMI) through study completion, an average of 1 year kg/m2
Trial Locations
- Locations (1)
Mersin University Faculty of Medicine
Mersin, Mersin, Turkey (Türkiye)
Mersin University Faculty of MedicineMersin, Mersin, Turkey (Türkiye)